Penumbra (PEN)

• Market cap: $11.2B
• 1 day: -3.77%
• 5 days: 6.90%
• 1 month: 8.75%
• 3 months: 21.29%
• 6 months: 49.42%
• Year to date: 21.54%
• 1 year: 12.92%
• 5 years: 51.82%
• 10 years: 606.25%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Employees: 4,500

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

562% more call options, than puts

Call options by funds: $63.7M | Put options by funds: $9.62M

168% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 25

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

21% more capital invested

Capital invested by funds: $6.87B [Q3] → $8.29B (+$1.42B) [Q4]

11% more funds holding

Funds holding: 329 [Q3] → 364 (+35) [Q4]

0.08% less ownership

Funds ownership: 91.0% [Q3] → 90.93% (-0.08%) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 120 | Existing positions reduced: 131

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $245 16% downside
• Avg. target: $299 2% upside
• High target: $340 17% upside

13 analyst ratings

• positive: 11 85%
• neutral: 2 15%
• negative: 0 0%

JP Morgan Robert Marcus 100% 1-year accuracy 1 / 1 met price target	2% downside $285	Overweight Maintained	19 Feb 2025
Truist Securities David Rescott 89% 1-year accuracy 16 / 18 met price target	11% upside $325	Buy Maintained	19 Feb 2025
RBC Capital Shagun Singh 63% 1-year accuracy 44 / 70 met price target	7% upside $313	Outperform Maintained	19 Feb 2025
Canaccord Genuity Jason Mills 67% 1-year accuracy 6 / 9 met price target	17% upside $340	Buy Maintained	19 Feb 2025
UBS Priya Sachdeva 67% 1-year accuracy 2 / 3 met price target	10% upside $320	Buy Maintained	19 Feb 2025